Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 45

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 45
---
   Provision for genomic screening services  Trading of industrial chemicals  Provision for genomic screening services  Trading of industrial chemicals   Three months ended March 31, 2025  Three months period March 31, 2024              REVENUE $3,068  $2,134,007  $3,165  $2,378,686                  COST OF REVENUE  (1,406)  (1,792,176)  (2,252)  (2,014,568)                 GROSS PROFIT  1,662   341,831   913   364,118                  OTHER INCOME                Dividend income   -   8,934   -   8,946 Interest income  20,002   3,566   23,783   5,200 Fair value gain on investments in equity securities  -   4,514   -   84,785 Gain on disposal of investments in equity securities  -   -   -   6,181 Reversal of expected credit losses  -   25,153   -   31,752 Others  3,893   25,358   14,911   26,289 TOTAL OTHER INCOME  23,895   67,525   38,694   163,153                  OPERATING EXPENSES                Sales and marketing  (27,640)  (508,990)  (31,105)  (120,442)Research and development  (12,139)  -   (11,475)  - General and administrative  (56,006)  (125,133)  (38,275)  (130,421)Fair value loss on investments in equity securities  -   (68,497)  -   (44,297)Provision for expected credit losses   -   (40,124)  -   (120,469)TOTAL OPERATING EXPENSES  (95,785)  (742,744)  (80,855)  (415,629)